Interv Akut Kardiol. 2020;19(2):122-124 | DOI: 10.36290/kar.2020.029
Fixed combination of atorvastatin and ezetimibe in the dyslipidemia treatment
- Centrum preventivní kardiologie, Univerzita Karlova, Lékařská fakulta v Plzni
- 2 . interní klinika Fakultní nemocnice Plzeň
Primary and secondary prevention of atherosclerotic cardiovascular diseases (ASCVD) stays to be one of the Czech health care priorities. The ABC of ASCVD prevention is healthy life style and LDL-cholesterol (ch), the most causal risk factor among all, reduction. To reach the new ambicious LDL-ch aims is impossible by only statin monotherapy. Combination of statin and ezetimibe has got the highest class of recommendation. That fixed combination is very effective, well tolerated and improves therapy adherence. It is eligible for all patients with very high or high global cardiovascular risk. The advantages of atorvastatin and ezetimibe fixed combination in patients after acute coronary syndrome and /or in patients with renal failure are mentioned.
Keywords: hypercholesterolemia management, cardiovascular disease, combination of statin and ezetimibe.
Published: June 2, 2020 Show citation
References
- Bruthans J, Cífková R, Lánská V, et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014; 21: 829-839.
Go to original source... - Mach E, Baigent C, Catapano AL, et al. Task Force Members: 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal (2019): 1-78. doi: 10.1093/eurheartj/ehz455. Go to original source...
- Catapano AL, Graham I, De Backer G, et al. Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Europ Heart J 2016. doi: 10.1093/eurheartj/ehw272. Go to original source...
- Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681. Go to original source...
- Stroes ES, Thompson PD, Corsini A, et al. EuropeanAtherosclerosis Society Consensus Panel. Statin-associatedmusclesymptoms: impal on statintherapy - EuropeanAtherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Europ Heart J 2015; 36(17): 1012-1022. doi: 10.1093/eurheartj/ehv043. Go to original source...
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndrome. MEJM 2015; 372: 2387-2397. Go to original source...
Go to PubMed... - Kenichi Tsujita, Seigo Sugiyama, Hitoshi Sumida, et al. Impact of dual lipid-lowering strategy with Ezetimibe and Atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention. The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015; 66(5): 495-507. doi: 10.1016/j.jacc.2015.05.065 Go to original source...
- Takase H, Dohi Y, Okado T, et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Eur J Clin Invest 2012; 42: 1287-94. Go to original source...
- Hiramitsu S, Miyagshima K, Ishii J, et al. The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012; 60: 395-400. Go to original source... Go to PubMed...